Abbvie Inc logo

ABBV - Abbvie Inc Share Price

$106.11 -0.6  -0.6%

Last Trade - 08/03/21

Large Cap
Market Cap £135.55bn
Enterprise Value £191.68bn
Revenue £33.13bn
Position in Universe 54th / 6668
Unlock ABBV Revenue
Relative Strength (%)
1m -0.54%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.44%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
22,859 25,638 28,216 32,753 33,266 45,804 53,766 57,046 +14.9%
+151.5 +13.6 +4.5 +59.2 -8.3 -36.4 +233.5 +11.7
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AbbVieInc revenues increased 38% to $45.8B. Net income applicableto common stockholders decreased 42% to $4.56B. Revenuesreflect United States segment increase of 40% to $33.81B.Net income was offset by Selling, general andadministrative increase of 61% to $9.04B (expense), Other(income) expense, net increase of 87% to $5.61B (expense).Dividend per share increased from $4.28 to $4.72.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ABBV
Graphical History


ABBV Revenue Unlock ABBV Revenue

Net Income

ABBV Net Income Unlock ABBV Revenue

Normalised EPS

ABBV Normalised EPS Unlock ABBV Revenue

PE Ratio Range

ABBV PE Ratio Range Unlock ABBV Revenue

Dividend Yield Range

ABBV Dividend Yield Range Unlock ABBV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABBV EPS Forecasts Unlock ABBV Revenue
Profile Summary

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated April 10, 2012
Public Since January 2, 2013
No. of Shareholders: 47,754
No. of Employees: 47,000
Sector Healthcare
Industry Pharmaceuticals
Exchange New York Stock Exchange
Shares in Issue 1,765,881,690
Free Float (0.0%)
Eligible for
ABBV Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ABBV
Upcoming Events for ABBV
Thursday 29th April, 2021 Estimate
Q1 2021 Abbvie Inc Earnings Release
Frequently Asked Questions for Abbvie Inc
What is the Abbvie Inc share price?

As of 08/03/21, shares in Abbvie Inc are trading at $106.11, giving the company a market capitalisation of £135.55bn. This share price information is delayed by 15 minutes.

How has the Abbvie Inc share price performed this year?

Shares in Abbvie Inc are currently trading at $106.11 and the price has moved by 19.47% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abbvie Inc price has moved by -14.59% over the past year.

What are the analyst and broker recommendations for Abbvie Inc?

Of the analysts with advisory recommendations for Abbvie Inc, there are there are currently 6 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Abbvie Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Abbvie Inc next release its financial results?

Abbvie Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Abbvie Inc dividend yield?

The Abbvie Inc dividend yield is 4.45% based on the trailing twelve month period.

Does Abbvie Inc pay a dividend?

Last year, Abbvie Inc paid a total dividend of 4.72, and it currently has a trailing dividend yield of 4.45%. Looking ahead, shares in Abbvie Inc are due to go ex-dividend on 2021-04-14 and the next dividend pay date is 2021-05-14.

When does Abbvie Inc next pay dividends?

Abbvie Inc are due to go ex-dividend on 2021-04-14 and the next dividend pay date is 2021-05-14. The historic dividend yield on Abbvie Inc shares is currently 4.45%.

How do I buy Abbvie Inc shares?

To buy shares in Abbvie Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Abbvie Inc?

Shares in Abbvie Inc are currently trading at $106.11, giving the company a market capitalisation of £135.55bn.

Where are Abbvie Inc shares listed? Where are Abbvie Inc shares listed?

Here are the trading details for Abbvie Inc:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: ABBV
What kind of share is Abbvie Inc?

Based on an overall assessment of its quality, value and momentum, Abbvie Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Abbvie Inc share price forecast 2021?

Shares in Abbvie Inc are currently priced at $106.11. At that level they are trading at 4.37% discount to the analyst consensus target price of 0.00.

Analysts covering Abbvie Inc currently have a consensus Earnings Per Share (EPS) forecast of 12.205 for the next financial year.

How can I tell whether the Abbvie Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbvie Inc. Over the past six months, the relative strength of its shares against the market has been 0.65%. At the current price of $106.11, shares in Abbvie Inc are trading at 8.68% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Abbvie Inc PE Ratio?

The Abbvie Inc PE ratio based on its reported earnings over the past 12 months is 29. The shares are currently trading at $106.11.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Abbvie Inc?

Abbvie Inc's management team is headed by:

William Chase - EVF
Richard Gonzalez - CHM
Timothy Richmond - CHO
Azita Saleki-Gerhardt - EVP
Laura Schumacher - VMG
Carlos Alban - VMG
Robert Alpern - IND
Roxanne Austin - IND
William Burnside - IND
Glenn Tilton - LED
Michael Severino - PRE
Henry Gosebruch - EVP
Robert Michael - CFO
Nicholas Donoghoe - SVP
Thomas Freyman - IND
Who are the major shareholders of Abbvie Inc?

Here are the top five shareholders of Abbvie Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.07% (142.6m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.68% (82.7m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.43% (78.2m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.82% (49.8m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 2.15% (37.9m shares)
Similar to ABBV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.